A varied clinical picture
Among 32 people with loss-of-function variants in WDFY3, all had signs of neurodevelopmental delay or intellectual disability. The paper in Molecular Psychiatry reports autism diagnoses in 23 and attention-deficit hyperactivity symptoms in nine. Those numbers make a clinical pattern visible. Mild or absent features in some relatives carrying inherited variants show that the pattern does not look the same in every person.[1]
WDFY3 helps cells route accumulating proteins for selective breakdown. When researchers reduced its level in a human-derived neuronal cell line, clearance of protein aggregates faltered. Cell proliferation increased, while extensions of differentiating cells became shorter. These experiments identify a testable route from the gene to neuronal development. They do not identify a single cause for every feature observed in people.[1]
Lithium in cells
Lithium chloride raised WDFY3 expression in cultured cells and increased branching in cortical neurons taken from mouse embryos with one inactive copy of Wdfy3. Both measurements concern cells in a laboratory, not a child’s development or daily functioning. The authors also report that the branching response in mouse neurons was not explained mainly by the expected beta-catenin route. The path through which lithium acted remains unsettled.[1]
The human part of the paper describes observed clinical features; the lithium part tests cells and mouse material. None of the 32 people received lithium for WDFY3 in this research. Reading restored branching in a dish as recovery in a patient would overrun the evidence. The study’s strength is placing a varied human phenotype beside a biological test. Its missing step is measurement of benefit and harm in affected people.[1]
The missing patient step
Of 24 people with head measurements, 21 had a large or high-normal circumference, while another person carrying a truncating variant had a relatively small measurement. That variation makes a single measurement a poor basis for a firm developmental forecast for a family. The cases were brought together through clinics in several countries; such recruitment does not measure the full range among all carriers in the population.[1]
The patient-relevant next question is whether greater branching in a laboratory can translate into a safe intervention that improves everyday development. This study does not answer it. I read the WDFY3 finding as a step toward explaining variable features and designing further experiments. When discussing treatment prospects with families, the distance between a cell measurement and human benefit has to remain visible.[1]